Compare ResMed Inc. (RMD) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Williams-Sonoma, Inc. — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.83B). The key difference: ResMed Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays the higher dividend (1.33%). Which is the better fit depends on your goals.
| RMD | WSM | |
|---|---|---|
Market Cap | $31.89B | $26.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $283.28 | $251.81 |
52-Week Low | $182.82 | $168.64 |
Enterprise Value | $31.24B | $27.33B |
Dividend Yield | 1.19% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.10 beating expectations of $2.08. Revenue trends show stabilization around $7.7-8.0B with improving net margins to 14.73%. Technical indicators show the stock testing support at $225 with RSI at oversold levels, suggesting potential near-term bounce.
The outlook remains positive with analyst consensus target of $252.23 representing 10.7% upside. Strong market share gains in home furnishings and raised full-year guidance support bullish case, though tariff pressures and competitive retail environment present ongoing risks. Institutional buying activity, including HSBC's 12.1% position increase, reinforces confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
